Why are Immupharma plc, Purplebricks Group plc and Roxi Petroleum plc among today’s major movers?

Should you buy or sell these 3 big movers? Immupharma plc (LON: IMM), Purplebricks Group plc (LON: PURP) and Roxi Petroleum plc (LON: RXP)

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Shares in online estate agency Purplebricks (LSE: PURP) have soared by around 7% today despite no news flow having been released by the company. This is somewhat surprising since it was announced today that the Royal Institute of Chartered Surveyors (RICS) expects house prices to fall in the next few months as fears surrounding the EU referendum and changes to the tax system cause demand for property to wane.

Despite this concern about house prices, Purplebricks continues to move higher and has now recorded share price gains of 45% since the turn of the year. However, the scope for further gains could be somewhat limited. Certainly, there is a major opportunity for web-based estate agencies such as Purplebricks to encroach on traditional estate agency business. But with Purplebricks trading on a forward price-to-earnings (P/E) ratio of around 44, it appears to lack a margin of safety.

With the EU referendum just around the corner, house prices set to fall and interest rates likely to rise over the medium term, such a high valuation may cause investment returns from Purplebricks to disappoint.

Also rising today are shares in Immupharma (LSE: IMM). The drug discovery and development company is up by 9% today and this takes its share price rise to 46% in the last week after it announced that it has made progress with its development of a treatment to fight life-threatening autoimmune disease Lupus. As part of its phase 3 trials, Immupharma has begun dosing Lupus sufferers with its Lupuzor treatment at its first European sites in addition to US sites.

Clearly, this is excellent news for the company’s investors and it shows that sentiment towards a stock can rapidly change. Looking ahead, further updates on Lupuzor are anticipated in the short to medium term and they have the potential to push Immupharma’s share price higher. As such, it may be of further interest to less risk averse investors, although it remains a relatively small and higher risk healthcare play.

Meanwhile, shares in Roxi Petroleum (LSE: RXP) have fallen by over 4% today despite no news flow having been released by the company. Its latest news was a set of rather disappointing results which showed that the oil producer has swung into a loss in its most recent financial year. In fact, following a $20m pretax profit in 2014, Roxi Petroleum recorded a near-$2m loss in 2015. That was due in part to the lack of a reversed impairment from 2014 which was not repeated in 2015. However, the fact that Roxi Petroleum avoided impairments at all in 2015 was a positive result for its investors.

Looking ahead, Roxi Petroleum is aiming to increase production in the current year. Furthermore, it is intent on taking advantage of lower costs to develop its BNG asset and it therefore has long term growth potential for less risk averse investors. However, with there being a number of other oil and gas stocks which are profitable and priced to sell, there may be better options elsewhere.

Peter Stephens has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Mature black woman at home texting on her cell phone while sitting on the couch
Investing Articles

The FTSE 100 hits 10,000! What does this mean for investors?

The FTSE 100 -- the blue-chip stock index -- has reached an all-time high, representing a milestone for the supposedly…

Read more »

British coins and bank notes scattered on a surface
Investing Articles

How much do you need in an ISA for £2,026 passive income a month?

What kind of nest egg would an investor need for £2,026 monthly passive income? Our author crunches the numbers required…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

Warren Buffett has retired. Could his investing approach still work today?

Warren Buffett has handed over the reins at Berkshire Hathaway. He's been investing for decades and the world has changed.…

Read more »

ISA coins
Investing Articles

Got a spare £20k for a Stocks and Shares ISA? Here’s how it could generate a £1,400 passive income in 2026!

A Stocks and Shares ISA can be a serious source of long-term passive income. Christopher Ruane explains more about this…

Read more »

Growth Shares

2 of the cheapest FTSE stocks to consider buying as we hit 2026

Jon Smith calls out a couple of FTSE companies that have fallen in the past year that he believes are…

Read more »

Tesla building with tesla logo and two teslas in front
Investing Articles

Why Tesla stock outperformed the S&P 500 — again — in 2025

As the Tesla share price shrugs off declining revenues and profits to climb 19%, what kind of further excitement will…

Read more »

Black woman using smartphone at home, watching stock charts.
Investing Articles

Thinking of investing in the stock market? Keep these basic rules in mind

Investing in the stock market can put investors on the fast track to building wealth and earning passive income. And…

Read more »

piggy bank, searching with binoculars
US Stock

This Dow Jones stock could be a dark horse outperformer for 2026

Jon Smith looks across the pond and spots a Dow Jones company that has fallen by 11% in the past…

Read more »